PT-141 Peptide (Bremelanotide): Benefits, Research Uses, Storage, and Reconstitution Guide

PT-141 Peptide (Bremelanotide): Benefits, Research Uses, Storage, and Reconstitution Guide

This article is written for educational and laboratory research purposes only.

What Is PT-141?

PT-141, also known as Bremelanotide, is a synthetic peptide derived from Melanotan II.

It was developed for central nervous system research, not hormonal replacement.

Unlike PDE5 inhibitors, PT-141 acts on the melanocortin receptors (MC3R and MC4R) in the brain.

This mechanism makes it a key research compound in studies involving:

  • Sexual motivation

  • Arousal pathways

  • Neurobehavioral signaling

PT-141 Peptide Benefits (Research-Based)

1. Central Arousal Pathway Activation

  • Acts on the brain, not blood vessels

  • Independent of testosterone, estrogen, or nitric oxide

  • Studied in both male and female models

2. Female Sexual Interest Research

  • Explored for hypoactive sexual desire disorder (HSDD)

  • Targets desire and motivation rather than physical performance

3. Male Libido and Erectile Response Research

  • Investigated for psychogenic erectile dysfunction

  • May support arousal where anxiety or neurological factors are present

4. Neurological and Behavioral Studies

  • Melanocortin system involvement in mood and reward

  • Ongoing research in neuroendocrine signaling

How PT-141 Is Reconstituted (Educational Overview)

This section is for laboratory and research education only.

PT-141 is supplied as a lyophilised (freeze-dried) powder.

Common Research Reconstitution Method

  • Use bacteriostatic water

  • Slowly introduce diluent down the vial wall

  • Do not shake

  • Gently swirl until fully dissolved

The final concentration depends on:

  • Vial strength (commonly 5 mg or 10 mg)

  • Volume of bacteriostatic water added

Always label:

  • Concentration

  • Date of reconstitution

Storage Guidelines (Research Standard)

Unreconstituted PT-141

  • Store at 2–8°C

  • Protect from light

  • Keep sealed until use

Reconstituted PT-141

  • Refrigerate at 2–8°C

  • Do not freeze

  • Use within 28–30 days under sterile conditions

Discard if:

  • Solution becomes cloudy

  • Particles appear

  • Sterility is compromised

PT-141 Dosage Information (Research Context Only)

Not medical advice.
Not for human consumption in Australia.

In published clinical and pre-clinical research:

  • Typical study ranges: 0.5 mg – 2 mg per administration

  • Onset observed between 30–60 minutes

  • Effects studied for up to 6–12 hours

Dose-response varies significantly due to:

  • CNS sensitivity

  • Melanocortin receptor expression

  • Individual neurochemistry

Safety and Adverse Effects (Observed in Studies)

Reported in controlled trials:

  • Transient nausea

  • Facial flushing

  • Headache

  • Increased blood pressure (temporary)

These findings reinforce the need for controlled research environments only.

Regulatory Status in Australia

  • Not listed on the ARTG

  • Not approved for human or veterinary use

  • Legal for research supply only

Back to blog